In a landmark development for oncology, a groundbreaking clinical trial has revealed that administering immunotherapy prior to surgery can dramatically alter the treatment landscape for patients with specific forms of colorectal cancer. The NEOPRISM-CRC study, led by researchers at University College London (UCL) and University College London Hospitals (UCLH), has demonstrated that a short, intensive course of immunotherapy—replacing the traditional post-surgical chemotherapy—can yield long-term, cancer-free survival.
The results, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, suggest that this "pre-habilitation" approach may offer not only superior clinical outcomes but also a higher quality of life for patients. For many, the prospect of avoiding the grueling side effects of traditional chemotherapy is no longer a distant hope, but a tangible clinical reality.
The NEOPRISM-CRC Trial: A New Clinical Frontier
The NEOPRISM-CRC trial represents a significant departure from standard medical practice. Historically, the treatment protocol for stage two or three colorectal cancer has involved surgical intervention followed by several months of systemic chemotherapy. While effective, this regimen is often associated with significant toxicity and physical decline.
The study focused on 32 patients diagnosed with a specific genetic subtype of colorectal cancer known as MMR-deficient (mismatch repair deficient) or MSI-high (microsatellite instability-high). This subtype, which affects roughly 10% to 15% of colorectal cancer patients—translating to approximately 2,000 to 3,000 individuals in the UK annually—is characterized by a specific inability to repair DNA errors, making it particularly responsive to immunotherapy.
Instead of the conventional surgical-first approach, participants in this trial received pembrolizumab—a potent immune checkpoint inhibitor—for a period of just nine weeks before undergoing surgery. The objective was to prime the immune system to recognize and eliminate tumor cells before the primary mass was surgically removed.
Chronology of Success: From Diagnosis to Long-Term Remission
The efficacy of the NEOPRISM-CRC trial is perhaps best illustrated by the sustained health of its participants. Following the nine-week course of pembrolizumab, the trial observed an immediate and profound impact on tumor progression.
The Immediate Response
Early data from the trial were striking: 59% of patients exhibited no detectable cancer after completing the immunotherapy course and the subsequent surgery. For these patients, the treatment effectively "melted" the tumors, a testament to the potency of mobilizing the body’s own immune defenses against malignant cells.
The 33-Month Milestone
The most compelling evidence, however, comes from the long-term follow-up. After 33 months—nearly three years post-treatment—the researchers reported that not a single patient in the cohort had experienced a relapse. Even those who still had minor traces of cancer detected post-treatment saw no evidence of growth or metastasis. This result stands in stark contrast to standard care, where approximately 25% of patients typically experience a cancer recurrence within three years of surgery and chemotherapy.
Data-Driven Precision: Personalized Blood Tests
A critical component of the NEOPRISM-CRC study was the integration of cutting-edge diagnostics. Working alongside the biotech firm Personalis, the research team developed personalized blood tests designed to detect circulating tumor DNA (ctDNA).
This methodology allows for a level of precision previously unattainable in routine clinical care. By monitoring the blood for the presence of cancer DNA, clinicians can determine with high accuracy whether the immunotherapy is successfully eradicating the tumor. If the ctDNA disappears from the bloodstream, it serves as a robust biological indicator that the patient is likely to remain cancer-free for the long term.
These "liquid biopsies" are set to revolutionize how doctors manage treatment. Rather than a one-size-fits-all approach, these tests enable clinicians to tailor the intensity of treatment. Patients who show strong early responses may require less intensive intervention, while those at higher risk of disease progression can be identified early and provided with the necessary additional support.
Official Perspectives: Transforming the Standard of Care
The medical community has greeted the results with cautious optimism, viewing them as a potential blueprint for future cancer care.
Dr. Kai-Keen Shiu, Chief Investigator of the trial and a Consultant Medical Oncologist at UCLH, emphasized the significance of the findings. "Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging," Dr. Shiu noted. "It strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers."
Beyond the raw data, Dr. Shiu highlighted the human and practical implications of the findings. "What is particularly exciting is that we now may be able to predict who will respond to the treatment using personalized blood tests and immune profiling. These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy before and after surgery versus patients at higher risk of disease progression or relapse who need additional treatment."
Professor Marnix Jansen, also of the UCL Cancer Institute and UCLH, echoed these sentiments, noting that the study provides critical biological insights into why immunotherapy succeeds in this specific context. "These results not only confirm the durability of responses we saw almost three years ago, but also provide crucial biological insights into why immunotherapy is so effective in this setting," said Professor Jansen.
The Human Element: A Patient’s Journey
The clinical successes are mirrored in the personal accounts of trial participants. Christopher Burston, a 73-year-old from Portland, Dorset, was diagnosed with stage three colorectal cancer in early 2023. His journey began with routine screening, which detected blood in his stool—a common but often ignored symptom.
Following his diagnosis, Mr. Burston joined the NEOPRISM-CRC trial. He received three doses of pembrolizumab over nine weeks. By the time he underwent surgery in May 2023, the results were astounding. "The outcome of the surgery was essentially that the cancer had melted away," Mr. Burston recalled. "The immunotherapy had had an almost immediate effect."
Nearly three years later, Mr. Burston remains cancer-free. His story serves as a powerful reminder of the potential for medical innovation to restore quality of life. "I feel very lucky that I’ve reached the stage where my main problem is age rather than cancer or any illness," he said, reflecting on his return to a normal, active routine.
Implications for Future Oncology
The NEOPRISM-CRC study holds profound implications for the future of bowel cancer treatment, particularly given the rising incidence of the disease. Bowel cancer is currently the fourth most common cancer in the UK, with roughly 44,000 new cases diagnosed annually. While it remains a disease that primarily affects older populations, there is a documented rise in cases among adults under 50.
Survival rates for bowel cancer are heavily dependent on early detection and treatment efficacy. While stage one survival is high (around 90%), this drops significantly to 65% for stage three and just 10% for stage four. By moving the window of intervention to the pre-surgical period and utilizing immunotherapy, researchers hope to push these survival curves significantly higher.
Looking Ahead
The success of the NEOPRISM-CRC trial points toward a future where:
- Molecular Profiling is Standard: Routine genetic testing for MMR/MSI status could become a prerequisite for all new colorectal cancer diagnoses to identify candidates for immunotherapy.
- Dynamic Monitoring: The use of personalized blood tests to track ctDNA will likely replace traditional, less accurate follow-up methods, allowing for real-time adjustments to patient care plans.
- De-escalation of Treatment: By proving that short-term immunotherapy can be more effective than traditional long-term chemotherapy, the study paves the way for reduced toxicity and a significantly improved experience for the patient.
As the research moves toward larger, multi-center phase III trials, the medical community will be watching closely. If these results can be replicated in larger, more diverse populations, the NEOPRISM-CRC study may well be remembered as the moment the standard of care for colorectal cancer shifted from the reactive to the proactive—and from the systemic to the precision-based.
